Patent · US Active

Triazene compounds for the treatment of cancer

US8426390B2 · kind B2 · utility

0Cited by

0References

5Claims

0Family size

Assignee

Trin Therapeutics GmbH · DE

Inventors

Rudolf Reiter · Graz, AT
Jochen Kalbe · Leichlingen, DE
Heinz Forster · Wuppertal, DE

Key dates

Filing date	Aug 9, 2011
Grant date	Apr 23, 2013
Priority date	—
Expiry date	Oct 2, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D233/64
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.